LBT Innovations Ltd (ASX:LBT) has commenced a clinical study to validate the performance of APAS Independence’s automatic analysis of methicillin-resistant staphylococcus aureus (MRSA).
The APAS instrument is based upon LBT’s intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.
The new clinical study extends the application of APAS Independence into surveillance of critical organisms for infection control, which offers additional utility of the instrument.
Significant market opportunity
Samples for the detection of MRSA are routinely and regularly conducted in many hospitals and other health care facilities.
Testing for MRSA, along with Urine analysis, accounts for 50% to 70% of the culture plate volume in the target markets of Europe, the US and Australia.
The clinical study, being conducted in partnership with St Vincent’s Hospital, Melbourne, represents the final stage in the development of the MRSA analysis modules.
Custom clinical trial platform
LBT CEO and managing director Brent Barnes said: “The commencement of the MRSA clinical trial is another exciting development that will support the continued commercialisation of the APAS® technology by increasing the number of customers where the APAS® Independence provides clinical utility.
“It also signals LBT’s transition from technology invention to a software manufacturing process for future analysis modules.”
“I am also pleased to report that we have developed our own custom clinical trial platform to support the delivery of future clinical studies and ensure compliance with all regulatory requirements.”